Page 52 - Dermatitis News Today

There were no significant safety signals in the younger pediatric population, and no treatment-emergent adverse events suggestive of systemic JAK inhibition, Dr Lawrence Eichenfield said.

There remains a knowledge gap regarding the risk of JAK inhibitor use and VTE and/or MACE in the dermatologic population, the study authors wrote.

Retrospective study identifies potential for misdiagnosed mycosis fungoides and for dupilumab to fuel cutaneous lymphoid reactions that mimic mycosis fungoides in patients with atopic dermatitis.

Data were collected from adult caregivers of more than 3200 adolescents in the United States.

Results from OLYMPIA 1 provide further support for nemolizumab as a potential first-in-class prurigo nodularis treatment; in another study, a JAK inhibitor was beneficial in patients with PN.

Four institutions will receive grants to implement the model, which involved partnering with a local organization to provide an entry point for individuals in areas with limited access to medical care.

The product combines an antibiotic, a retinoid, and an antibacterial in a gel formulation.

Researchers from North Carolina State University have pinpointed a particular peptide's role in activating atopic dermatitis, or eczema. The work could lead to more effective treatments for the condition.

A man went to the emergency room with an itchy rash that covered his back and kept him up at night. He was diagnosed with shiitake dermatitis.

"This is the first study to demonstrate the therapeutic potential of rezpegaldesleukin," said Jonathan Silverberg, MD, PhD, MPH, who presented results of a phase 1b study.